‘Bullying’ Pharma Giants Charged South Africa More Than EU for COVID-19 Vaccines 05/09/2023 Kerry Cullinan Pharmaceutical giant Janssen/Johnson & Johnson (J&J) and generic manufacturer Serum Institute of India (SII) charged the South African government more than the European Union for COVID-19 vaccines – and South Africa assumed all the risk in ‘take-it-or-leave-it’ contracts with Pfizer, J&J and SII. This is according to an analysis of the contracts led by Health […] Continue reading -> UN Draft Pandemic Declaration Offers ‘Little Hope’ for Strengthening Global Preparedness 01/09/2023 Stefan Anderson A draft political declaration on pandemics, due to be adopted by the United Nations General Assembly later this month, offers “little hope” that the UN process will make a difference in global pandemic preparedness, global health experts said on Friday. The document, made public on Thursday, is long on words but short on commitments. The […] Continue reading -> WHO Secures First COVID-19 Vaccine Licence from Private Pharmaceutical Company 31/08/2023 Stefan Anderson Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading -> GSK Sues Pfizer for Patent Violations over its RSV Vaccine 03/08/2023 Megha Kaveri Merely months after securing US Food and Drug Administration (FDA) approval for its Respiratory Syncytial Virus (RSV) vaccine, British pharma giant GSK has taken Pfizer to court for patent violations. GSK filed the lawsuit in a US federal court in Delaware on Wednesday alleging that Pfizer’s RSV vaccine, Abrysvo, violates four patents surrounding the antigen […] Continue reading -> Equitable Drug Access and Finance Are Looming Issues in Talks on International Health Regulations 28/07/2023 Elaine Ruth Fletcher The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. This was one […] Continue reading -> Lining Up Realistic Solutions if the ‘Holy Grail’ of the Pandemic Accord Fails 21/07/2023 Kerry Cullinan With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading -> Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
UN Draft Pandemic Declaration Offers ‘Little Hope’ for Strengthening Global Preparedness 01/09/2023 Stefan Anderson A draft political declaration on pandemics, due to be adopted by the United Nations General Assembly later this month, offers “little hope” that the UN process will make a difference in global pandemic preparedness, global health experts said on Friday. The document, made public on Thursday, is long on words but short on commitments. The […] Continue reading -> WHO Secures First COVID-19 Vaccine Licence from Private Pharmaceutical Company 31/08/2023 Stefan Anderson Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading -> GSK Sues Pfizer for Patent Violations over its RSV Vaccine 03/08/2023 Megha Kaveri Merely months after securing US Food and Drug Administration (FDA) approval for its Respiratory Syncytial Virus (RSV) vaccine, British pharma giant GSK has taken Pfizer to court for patent violations. GSK filed the lawsuit in a US federal court in Delaware on Wednesday alleging that Pfizer’s RSV vaccine, Abrysvo, violates four patents surrounding the antigen […] Continue reading -> Equitable Drug Access and Finance Are Looming Issues in Talks on International Health Regulations 28/07/2023 Elaine Ruth Fletcher The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. This was one […] Continue reading -> Lining Up Realistic Solutions if the ‘Holy Grail’ of the Pandemic Accord Fails 21/07/2023 Kerry Cullinan With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading -> Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
WHO Secures First COVID-19 Vaccine Licence from Private Pharmaceutical Company 31/08/2023 Stefan Anderson Three years after the launch of its COVID-19 Technology Access Pool (C-TAP) initiative, the World Health Organization (WHO) has secured its first COVID-19 vaccine license from a private pharmaceutical company, the UN health body announced on Tuesday. The agreement with Medigen Vaccine Biologics Corp., a private vaccine manufacturer based in Taiwan, is a welcome but underwhelming […] Continue reading -> GSK Sues Pfizer for Patent Violations over its RSV Vaccine 03/08/2023 Megha Kaveri Merely months after securing US Food and Drug Administration (FDA) approval for its Respiratory Syncytial Virus (RSV) vaccine, British pharma giant GSK has taken Pfizer to court for patent violations. GSK filed the lawsuit in a US federal court in Delaware on Wednesday alleging that Pfizer’s RSV vaccine, Abrysvo, violates four patents surrounding the antigen […] Continue reading -> Equitable Drug Access and Finance Are Looming Issues in Talks on International Health Regulations 28/07/2023 Elaine Ruth Fletcher The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. This was one […] Continue reading -> Lining Up Realistic Solutions if the ‘Holy Grail’ of the Pandemic Accord Fails 21/07/2023 Kerry Cullinan With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading -> Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
GSK Sues Pfizer for Patent Violations over its RSV Vaccine 03/08/2023 Megha Kaveri Merely months after securing US Food and Drug Administration (FDA) approval for its Respiratory Syncytial Virus (RSV) vaccine, British pharma giant GSK has taken Pfizer to court for patent violations. GSK filed the lawsuit in a US federal court in Delaware on Wednesday alleging that Pfizer’s RSV vaccine, Abrysvo, violates four patents surrounding the antigen […] Continue reading -> Equitable Drug Access and Finance Are Looming Issues in Talks on International Health Regulations 28/07/2023 Elaine Ruth Fletcher The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. This was one […] Continue reading -> Lining Up Realistic Solutions if the ‘Holy Grail’ of the Pandemic Accord Fails 21/07/2023 Kerry Cullinan With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading -> Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Equitable Drug Access and Finance Are Looming Issues in Talks on International Health Regulations 28/07/2023 Elaine Ruth Fletcher The thorny and unresolved issues of how to incorporate health equity measures and supportive finance for low and middle income countries into revisions of the WHO International Health Regulations (IHR), are set to be two key items on the agenda of an IHR negotiating body when talks resume again in early October. This was one […] Continue reading -> Lining Up Realistic Solutions if the ‘Holy Grail’ of the Pandemic Accord Fails 21/07/2023 Kerry Cullinan With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading -> Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Lining Up Realistic Solutions if the ‘Holy Grail’ of the Pandemic Accord Fails 21/07/2023 Kerry Cullinan With the fate and nature of the pandemic accord currently being negotiated by World Health Organization (WHO) member states still uncertain, global health experts are calling for “realistic” backup plans to protect the world against the next pandemic. “We need an ambitious but implementable pandemic accord – that is the Holy Grail,” Javier Guzman, Director […] Continue reading -> Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Agreement on TB Drug is ‘Stop Gap’ That Excludes High-Burden Countries in Eastern Europe and Central Asia 14/07/2023 Kerry Cullinan The licensing agreement reached between Johnson & Johnson (J&J) and the Stop TB Partnership on Thursday to allow the generic production of the tuberculosis drug, bedaquiline, is simply a “stop-gap” measure that applies to a limited number of countries, according to Médecins Sans Frontières (MSF). At least nine countries in the Eastern Europe and Central […] Continue reading -> Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Medicines Patent Pool Announces Licenses for Generic COVID-19 Antiviral 27/06/2023 Stefan Anderson The Medicines Patent Pool (MPP) announced sublicensing agreements with seven manufacturers to produce and distribute generic versions of Japanese pharmaceutical company Shinogi’s COVID-19 antiviral treatment in 117 low- and middle-income countries. Ensitrelvir is an oral antiviral currently only approved in Japan under the country’s emergency regulatory approval system. The drug is being evaluated under a […] Continue reading -> Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pharma Shares COVID-19 Voluntary Licensing Lessons Amid Debate Over Best Path to Access Pandemic Products 15/06/2023 Megha Kaveri One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading -> Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Exclusive: Updated Pandemic Accord Draft Sees Watered Down Text on Publicly-Funded R&D; Pathogen Access and ‘Benefit Sharing’ Linkage Remain 24/05/2023 Elaine Ruth Fletcher A new “Zero+” version of a proposed World Health Organization pandemic accord being negotiated by member states has dropped previously strong language that conditioned use of public R&D funds to private sector commitments to price transparency and tech transfer of end products, among other measuress. However, the updated draft text, obtained by Health Policy Watch, […] Continue reading -> Posts navigation Older postsNewer posts